Physician profile
Jared Thomas Green
NPI 1104912708
$44,071.33
in general payments reported to CMS, 2019-2025
27 companies · $32K in 2025
The $32K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,173 · 2020: $220 · 2021: $1,590 · 2022: $3,662 · 2023: $3,651 · 2024: $2,184 · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $32K · Food and Beverage: $5,236 · Travel and Lodging: $519 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $31,650.00 |
| Food and Beverage | $5,236.42 |
| Travel and Lodging | $519.10 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $30,128.83 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $8,000.78 | 2019-2025 | Optimizer, Optimizer |
| Pfizer INC. | $1,500.84 | 2019-2025 | |
| Abbott Laboratories | $1,202.45 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $872.60 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $481.62 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $441.26 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $257.08 | 2019-2025 | Lifevest |
| Zoll Respicardia, INC. | $223.83 | 2022-2023 | Remede System |
| Astrazeneca Pharmaceuticals LP | $191.90 | 2022-2025 | Farxiga, Lokelma, Brilinta |
| Boston Scientific Corporation | $162.37 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.64 | 2019-2024 | Jardiance |
| Akcea Therapeutics, INC. | $102.34 | 2019-2020 | |
| Atricure, INC. | $59.00 | 2022 | |
| Medtronic, INC. | $40.00 | 2023 | Onyx Frontier |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $37.42 | 2025 | Zepbound |
| Actelion Pharmaceuticals US, INC. | $35.79 | 2019 | |
| Mannkind Corporation | $28.33 | 2025 | |
| Alnylam Pharmaceuticals INC. | $24.90 | 2025 | Onpattro |
| Lantheus Medical Imaging, INC. | $21.58 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $20.40 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2025 | |
| United Therapeutics Corporation | $17.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.89 | 2019 | |
| Amgen INC. | $14.76 | 2019 | |
| Inspire Medical Systems, INC. | $13.27 | 2023 | Inspire |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.